(Q24246084)

1

0 references

Niall J Furlong

2

0 references

Gerlof D Valk

3

0 references

Guy EHM Rutten

Cochrane Database of Systematic Reviews

5

0 references

publication date

18 October 2004

0 references

published in

0 references

cites work

[Effectiveness of combined treatment with glibenclamide and insulin in secondary sulfonylurea failure. A controlled multicenter double-blind clinical trial]

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003418.PUB2

Insulin lispro in the treatment of patients with type 2 diabetes mellitus after oral agent failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003418.PUB2

Comparison of insulin with or without continuation of oral hypoglycemic agents in the treatment of secondary failure in NIDDM patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003418.PUB2

Glyburide decreases insulin requirement, increases beta-cell response to mixed meal, and does not affect insulin sensitivity: effects of short- and long-term combined treatment in secondary failure to sulfonylurea

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003418.PUB2

Sulphonylurea failure in type 2 diabetes: treatment with a basal insulin supplement.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003418.PUB2

Causes of weight gain during insulin therapy with and without metformin in patients with Type II diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003418.PUB2

Insulin versus a combination of insulin and sulfonylurea in the treatment of NIDDM patients with secondary oral failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003418.PUB2

Efficacy of bedtime NPH insulin with daytime sulfonylurea for subpopulation of type II diabetic subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003418.PUB2

Combined therapy for obese type 2 diabetes: suppertime mixed insulin with daytime sulfonylurea

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003418.PUB2

Beginning insulin treatment of obese patients with evening 70/30 insulin plus glimepiride versus insulin alone. Glimepiride Combination Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003418.PUB2

Bedtime insulin/daytime glipizide. Effective therapy for sulfonylurea failures in NIDDM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003418.PUB2

Comparison of different insulin regimens in elderly patients with NIDDM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003418.PUB2

Comparison of insulin regimens in patients with non-insulin-dependent diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003418.PUB2

Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. A randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003418.PUB2

Therapy focused on lowering postprandial glucose, not fasting glucose, may be superior for lowering HbA1c. IOEZ Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003418.PUB2

Trial of sulfonylurea in combination with insulin in the therapy of diabetes type I and II. Evidence against a primary extrapancreatic receptor effect.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003418.PUB2

A long-term, randomized, comparative study of insulin versus sulfonylurea therapy in type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003418.PUB2

Insulin-glyburide combination therapy for non-insulin-dependent diabetes mellitus: a long-term double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003418.PUB2

Gliclazide and bedtime insulin are more efficient than insulin alone for type 2 diabetic patients with sulfonylurea secondary failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003418.PUB2

The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. A multicenter controlled clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003418.PUB2

Initiation of insulin treatment after 70 years of age: patient status 2 years later.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003418.PUB2

Combination insulin/glyburide therapy in type II diabetes mellitus. Effects on lipoprotein metabolism and glucoregulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003418.PUB2

Modification of postprandial hyperglycemia with insulin lispro improves glucose control in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003418.PUB2

Combination insulin and sulfonylurea therapy in insulin-requiring type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003418.PUB2

Effects of tolazamide and exogenous insulin on pattern of postprandial carbohydrate metabolism in patients with non-insulin-dependent diabetes mellitus. Results of randomized crossover trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003418.PUB2

Long-term effects of troglitazone: open-label extension studies in type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003418.PUB2

Intensive insulin therapy combined with metformin in obese type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003418.PUB2

Metformin for obese, insulin-treated diabetic patients: improvement in glycaemic control and reduction of metabolic risk factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003418.PUB2

Different effects of insulin and oral antidiabetic agents on glucose and energy metabolism in type 2 (non-insulin-dependent) diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003418.PUB2

Effects of combination of insulin and acarbose compared with insulin and gliclazide in type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003418.PUB2

Acarbose for the treatment of type II diabetes: the results of a Canadian multi-centre trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003418.PUB2

Efficacy and safety of acarbose in insulin-treated patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003418.PUB2

Comparison of Bedtime NPH or Preprandial Regular Insulin Combined With Glibenclamide in Secondary Sulfonylurea Failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003418.PUB2

The role of sulphonylurea in combination therapy assessed in a trial of sulphonylurea withdrawal. Scandinavian Insulin-Sulphonylurea Study Group Research Team.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003418.PUB2

New modalities in diabetes treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003418.PUB2

Combination insulin-sulfonylurea therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003418.PUB2

Effects of combined insulin-sulfonylurea therapy in type II patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003418.PUB2

Acarbose vs. bedtime NPH insulin in the treatment of secondary failures to sulphonylurea-metformin therapy in type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003418.PUB2

Glyburide or insulin for metabolic control in non-insulin-dependent diabetes mellitus. A randomized, double-blind study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003418.PUB2

Concomitant insulin and sulfonylurea therapy in patients with type II diabetes. Effects on glucoregulation and lipid metabolism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003418.PUB2

Effect of insulin versus sulfonylurea therapy on cardiovascular risk factors and fibrinolysis in type II diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003418.PUB2

Metabolic effects of combination glipizide and human proinsulin treatment in NIDDM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003418.PUB2

Nicotinamide improves insulin secretion and metabolic control in lean type 2 diabetic patients with secondary failure to sulphonylureas

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003418.PUB2

Combined metformin and insulin therapy for patients with type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003418.PUB2

A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003418.PUB2

Adding metformin versus insulin dose increase in insulin-treated but poorly controlled Type 2 diabetes mellitus: an open-label randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003418.PUB2

The effects of metformin on glycemic control and serum lipids in insulin-treated NIDDM patients with suboptimal metabolic control.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003418.PUB2

Effects of insulin therapy upon plasma lipid fatty acids and platelet aggregation in NIDDM with secondary failure to oral antidiabetic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003418.PUB2

Insulin and sulfonylurea therapy in NIDDM patients. Are the effects on lipoprotein metabolism different even with similar blood glucose control?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003418.PUB2

One-year response to evening insulin therapy in non-insulin-dependent diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003418.PUB2

Effects of short-term insulin therapy upon therapeutic response to glipizide

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003418.PUB2

Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. Troglitazone and Exogenous Insulin Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003418.PUB2

Combination of insulin with glipizide increases peripheral glucose disposal in secondary failure type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003418.PUB2

Comparison of morning or bedtime insulin with and without glyburide in secondary sulfonylurea failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003418.PUB2

Insulin and sulphonylurea in the therapy of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003418.PUB2

Effect of acarbose on additional insulin therapy in type 2 diabetic patients with late failure of sulphonylurea therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003418.PUB2

Effects of the combination of insulin and glibenclamide in type 2 (non-insulin-dependent) diabetic patients with secondary failure to oral hypoglycaemic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003418.PUB2

Pramlintide, a synthetic analog of human amylin, improves the metabolic profile of patients with type 2 diabetes using insulin. The Pramlintide in Type 2 Diabetes Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003418.PUB2

Comparison of combined therapies in treatment of secondary failure to glyburide

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003418.PUB2

Efficacy of combined treatments in NIDDM patients with secondary failure to sulphonylureas. Is it predictable?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003418.PUB2

Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003418.PUB2

A randomized crossover study of sulphonylurea and insulin treatment in patients with type 2 diabetes poorly controlled on dietary therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003418.PUB2

Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003418.PUB2

A comparison of troglitazone and metformin on insulin requirements in euglycemic intensively insulin-treated type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003418.PUB2

Combined bedtime insulin--daytime sulphonylurea regimen compared with two different daily insulin regimens in type 2 diabetes: effects on HbA1c and hypoglycaemia rate--a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003418.PUB2

Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003418.PUB2

A randomized controlled trial of weight reduction and exercise for diabetes management in older African-American subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003418.PUB2

Statistical Methods in Medical Research

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003418.PUB2

A Coefficient of Agreement for Nominal Scales

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003418.PUB2

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003418.PUB2

Well-being and symptoms in relation to insulin therapy in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003418.PUB2

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003418.PUB2

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003418.PUB2

Benefits of combination therapy of insulin and oral hypoglycemic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003418.PUB2

Longitudinal study on glycaemic control and quality of life in patients with Type 2 diabetes mellitus referred for intensified control

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003418.PUB2

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003418.PUB2

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003418.PUB2

Quantitative synthesis in systematic reviews

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003418.PUB2

Insulin plus a Sulfonylurea Agent for Treating Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003418.PUB2

Is combination sulfonylurea and insulin therapy useful in NIDDM patients? A metaanalysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003418.PUB2

Timely addition of insulin to oral therapy for type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003418.PUB2

The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003418.PUB2

Insulin and risk of cardiovascular disease: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003418.PUB2

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003418.PUB2

Insulin and atheroma. 20-yr perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003418.PUB2

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003418.PUB2

Symptoms and well-being in relation to glycemic control in type II diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003418.PUB2

Combination therapies with insulin in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003418.PUB2

Risk factors for coronary artery disease in healthy persons with hyperinsulinemia and normal glucose tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003418.PUB2

Method Guidelines for Systematic Reviews in the Cochrane Collaboration Back Review Group for Spinal Disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003418.PUB2

Insulin and oral hypoglycemic agents should not be used in combination in the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003418.PUB2

7 January 2021

Treatment of poorly regulated non-insulin-dependent diabetes mellitus with combination insulin-sulfonylurea

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003418.PUB2

7 January 2021

Daytime glibenclamide and bedtime NPH insulin compared to intensive insulin treatment in secondary sulphonylurea failure: a 1-year follow-up

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003418.PUB2

7 January 2021

[Combination therapy with insulin/sulfonylurea in the long-term therapy of type II diabetes following "secondary failure"]

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003418.PUB2

7 January 2021

NIDDM: a rapid progressive disease. Results from a long-term, randomised, comparative study of insulin or sulphonylurea treatment

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003418.PUB2

7 January 2021

The influence of improved glycaemic control with insulin and sulphonylureas on acute phase and endothelial markers in Type II diabetic subjects

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003418.PUB2

7 January 2021

Morning or bed-time insulin with or without glibenclamide in elderly Type 2 diabetic patients unresponsive to oral antidiabetic agents

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003418.PUB2

7 January 2021

The lipoprotein profile differs during insulin treatment alone and combination therapy with insulin and sulphonylureas in patients with Type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003418.PUB2

7 January 2021

The effects of oral agent or insulin treatments on the plasma lipoproteins and the plasma lipoprotein lipase activator in diabetic patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003418.PUB2

7 January 2021

[Glibenclamide-insulin combination in the management of secondary failure of sulfonyl-urea medication]

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003418.PUB2

7 January 2021

Effects of tolazamide and exogenous insulin on insulin action in patients with non-insulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003418.PUB2

7 January 2021

Type II diabetes: insulin versus oral agents

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003418.PUB2

7 January 2021

Combined therapy of insulin and tolazamide decreases insulin requirement and serum triglycerides in obese patients with noninsulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003418.PUB2

7 January 2021

Glibenclamide improves the response to insulin treatment in non-insulin-dependent diabetics with second failure to sulfonylurea therapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003418.PUB2

7 January 2021

The effect of an alpha-glucosidase inhibitor and insulin on glucose metabolism and lipid profiles in non-insulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003418.PUB2

7 January 2021

The addition of glipizide to insulin therapy in type-II diabetic patients with secondary failure to sulfonylureas is useful only in the presence of a significant residual insulin secretion

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003418.PUB2

7 January 2021

C-peptide profiles in patients with non-insulin-dependent diabetes mellitus before and during insulin treatment.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003418.PUB2

7 January 2021

Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. National Diabetes Data Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003418.PUB2

7 January 2021

Effect of glyburide on glycemic control, insulin requirement, and glucose metabolism in insulin-treated diabetic patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003418.PUB2

7 January 2021

Effects of Combination Therapy With Glyburide and Insulin on Serum Lipid Levels in NIDDM Patients With Secondary Sulfonylurea Failure

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003418.PUB2

7 January 2021

Combination therapy for NIDDM with biosynthetic human insulin and glyburide

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003418.PUB2

7 January 2021

Morning or bedtime NPH insulin combined with sulfonylurea in treatment of NIDDM

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003418.PUB2

7 January 2021

Metformin added to insulin therapy in poorly controlled type 2 diabetes

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003418.PUB2

7 January 2021

Inside guidelines: comparative analysis of recommendations and evidence in diabetes guidelines from 13 countries

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003418.PUB2

7 January 2021

Medication compliance in non-insulin-dependent diabetes: a randomized comparison of chlorpropamide and insulin

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003418.PUB2

7 January 2021

Lack of effect of glibenclamide on insulin requirements and diabetic control in persons with insulin-dependent diabetes

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003418.PUB2

7 January 2021

United Kingdom Prospective Diabetes Study 24: a 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. United Kingd

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003418.PUB2

7 January 2021

Effects of metformin in patients with poorly controlled, insulin-treated type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003418.PUB2

7 January 2021

10.1002/14651858.CD003418.PUB2

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

1 reference

Consolidated OpenCitations Corpus – April 2017

PubMed publication ID

15495054

1 reference

Consolidated OpenCitations Corpus – April 2017